<SEC-DOCUMENT>0001193125-20-316343.txt : 20201214
<SEC-HEADER>0001193125-20-316343.hdr.sgml : 20201214
<ACCEPTANCE-DATETIME>20201214060909
ACCESSION NUMBER:		0001193125-20-316343
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201214
FILED AS OF DATE:		20201214
DATE AS OF CHANGE:		20201214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		201385020

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d58030d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 14 December 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g58030g1111171418263.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14 December
2020 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA RECEIVES 1.02 MILLION R&amp;D CASH REBATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 14&nbsp;December 2020, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to
confirm receipt of $1,018,448.10 from the Australian Taxation Office under the R&amp;D Tax Incentive Program for the financial year ending 30&nbsp;June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner said &#147;the R&amp;D tax rebate is an important, non-dilutive source of funding for the Company. The amount is consistent with
the expectations laid out in our financial reports, and the funds will be invested in progressing our clinical programs. This is an important year for Kazia, with multiple data read-outs anticipated over the coming months.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline
includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program
is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in
late 2016, paxalisib entered GBM AGILE, a pivotal study in glioblastoma, in October 2020. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February
2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g58030g1111171418263.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g58030g1111171418263.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X QD# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=PISUXSCG)J+[5<^:TOVF;S&78S^8=Q7&,$YSC'&*.4.8V+K_DG-E_V%9_\
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MB7)13325];F1I=G->7&^&41F/#;SS@TFIR737;1W<@9XN!M&!19&\M[_ ,B
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M%*^BWD-N9I1#$3,\"Q/*!*[H0&55ZG!(%7_M^F7/BG[?<R,($17#-"2LLZJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2\LN%RF<G.0?O'J*9#?6EFM^L$:S+)(C0+-&2  2>1GJ,TE&/5C<ZFJ2[?\
M!*L&FWESYGE0_P"J;8^Y@NUO3D]:A%M,8UD"'8TGE*<]6]/UK3LM1@:VNUO9
M5$T\XE+26_F@\'/'8\U'8W-D+1+>ZEEC\FY\]&2/=O& ,=>#P*.6(<\TW=%>
M'2KV=IECAR86*R NHVD=>IJNT$JQ)*4.QV**?4CJ/U%7%O8VGU.612INHW"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
